PPARG and lung adenocarcinoma: In EGFR-TKI-resistant lung adenocarcinoma cells, the PPARγ agonist, efatutazone, has been shown to trigger both apoptosis and cell cycle arrest via modulating the PPARγ/phosphatase and tensin homolog (PTEN)/AKT axis [41].